| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
In early August, I had the fortune to attend the Drug Discovery Technology and Development (DDT) 2005 conference, the 10th such conference to grace Boston. This was my fourth DDT conference in the last six years and although I can't offer a detailed analysis of the show in this short space, I can say that there definitely seems to have been a significant shift in the marketplace—or more appropriately, the players—over the last few years.
 
This shift is perhaps best exemplified by the changes I witnessed on the show's exhibit floor. No longer simply a place for the big instrument powerhouses to strut their collective stuff, practically swamping the messages of their smaller neighbors in the 10-by-10 booths, DDT has become a platform for an ever-increasing diversity of companies with a litany of small-cap companies making their presence known in fields such as analytical software, contract research, and specialty therapeutics.
 
No longer content to hide in or be swallowed by the shadows of the instrumentation and discovery giants, the new growth in the drug discovery arena is stretching its foliage to reach the sunlight. Where once small-cap players were only viewed as niche participants in the field, they are now seen as vital sources of innovation, complementing and supplementing the offerings of the instrument and discovery redwoods that surround them.
 
Where once small upstarts would be acquired or crushed by their larger brethren, they are now being viewed as viable partners for the development of specialist products or services, expanding the market shares of both partners without dramatically increasing the risks associated with new ventures. The perfect example of this is the collaboration of Silicon Graphics Inc. and Nallatech to develop high-performance computing solutions based on FPGA technologies; a story featured on the front page of the August 2005 issue of DDN (and below).
 
In this way, DDT2005 was very much a bellwether of the re-invigoration of the small-cap community and was therefore very much a positive sign of the industry growth we can expect in the future.
 
Randall C Willis
Executive Editor

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Clear cells with round, blue centers are shown against a varied blue background

Supercharging cell line development and engineering with automated single cell sorting

Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue